The management of Roventa-Henex has acquired 60% of the share capital of the company. The manufacturer of quality Swiss Made Private Label watches also designs, develops and distributes private label watches and related components. It was
Tags :Vischer
VISCHER has advised EBL on the sale of its Telekom division to Sunrise. EBL has been active in the telecom business since 2000 and owns telecom networks in around 200 communities in Switzerland. At the same time,
As we have informed last 28th July, Keda Industrial Group and Ningbo Shanshan were among the first companies which successfully listed global depositary receipts (
QoQa Brew, a subsidiary of QoQa Services, has financed its craft brewery through a security token offering. The brewery will be located in the “QG”, a co-working eco-friendly space imagine by QoQa Services, a leading
Mosanna Therapeutics, a Basel-based biotechnology company, has closed a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of the molecule MOS118 and for regulatory activities in
Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The
There is a merger in cruise brokerage. The two Swiss tourism companies e-hoi and Cruise Center also want to strengthen their bargaining power with the cruise lines. Business, down during the pandemic, is picking up
Valentino, the Italian luxury fashion house, will open a new boutique in Geneva on the prestigious Rue du Rhône. Valentino’s CEO Jacopo Venturini is repositioning the brand, further elevating its couture status and
VISCHER has advised Macquarie Bank on Swiss law issues in connection with a new USD 40 million credit facility for Trident Royalties, the London-based mining royalty and streaming company. Mayer Brown was the bank’s international
Eurocine Vaccines and Redbiotec have signed a research and collaboration agreement for the development of vaccine candidates against herpes simplex virus type 2. Under the terms of the agreement, Eurocine will have exclusive international rights to
